Sign in

ACIU on Nasdaq

AC Immune SA

In its 2026 annual report (Form 20-F) the company says: “We are a Swiss stock corporation ( société anonyme ) organized under the laws of Switzerland. Our Swiss enterprise identification number is CHE-109.878.825. Our common shares were admitted to trading on Nasdaq Global Market on September 23, 2016, and trade under the symbol ACIU.”5

$2.44 up 0.04 (1.46%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

3.6MRevenue, fiscal 20253
-70.4MNet income, fiscal 20253

Compare with MindMaze Therapeutics Holding SA or Altamira Therapeutics Ltd., or pick any stock.

  • TickerACIU on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersV81
  • Incorporated inSwitzerland4
  • Business addressEpfl Innovation Park, Building B, 1015 Lausanne, V8 000004
  • Filer categoryAccelerated filer4

See how the biggest companies compare on our leaderboards

We are a Swiss stock corporation ( société anonyme ) organized under the laws of Switzerland. We were formed as a Swiss limited liability company ( société à responsabilité limitée ) on February 13, 2003 with our registered office and domicile in Basel, Switzerland. We converted to a Swiss stock corporation ( société anonyme ) under the laws of Switzerland on August 25, 2003. Our Swiss enterprise identification number is CHE-109.878.825. Our domicile and registered office is in Ecublens, at the École Polytechnique Fédérale Lausanne (EPFL) Innovation Park Building B, 1015 Lausanne, Vaud, Switzerland. Our common shares were admitted to trading on Nasdaq Global Market on September 23, 2016, and trade under the symbol ACIU.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CHF, the currency the company reports in.

Key numbers, fiscal 2025

-1940.1%Operating margin3
-1971.6%Net margin3
-86.9%Revenue growth, 20253
-157.0%Return on equity3
-70.2M CHFFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢56.4M CHF
  • Interest0¢191.0K CHF

Out of 3.6M CHF in revenue.3 The company lost money this year.

Financial statements

Revenue67891033.6M CHF in 2025−48% since 2018
050.0M CHF100.0M CHF150.0M CHF2018: 6.9M CHF6.9M CHF20182019: 110.5M CHF110.5M CHF2019+1498%2020: 15.4M CHF15.4M CHF2020−86%2021: 0 CHF0 CHF20212022: 3.9M CHF3.9M CHF20222023: 14.8M CHF14.8M CHF2023+276%2024: 27.3M CHF27.3M CHF2024+85%2025: 3.6M CHF3.6M CHF2025−87%
Operating income6789103-69.3M CHF in 2025+40% since 2018
-100.0M CHF-50.0M CHF050.0M CHF2018: -49.5M CHF-49.5M CHF20182019: 44.5M CHF44.5M CHF20192020: -61.3M CHF-61.3M CHF20202021: -79.0M CHF-79.0M CHF2021+29%2022: -70.8M CHF-70.8M CHF2022−10%2023: -53.6M CHF-53.6M CHF2023−24%2024: -52.4M CHF-52.4M CHF2024−2%2025: -69.3M CHF-69.3M CHF2025+32%
Net income6789103-70.4M CHF in 2025+38% since 2018
-100.0M CHF-50.0M CHF050.0M CHF2018: -51.0M CHF-51.0M CHF20182019: 45.4M CHF45.4M CHF20192020: -61.9M CHF-61.9M CHF20202021: -73.0M CHF-73.0M CHF2021+18%2022: -70.8M CHF-70.8M CHF2022−3%2023: -54.2M CHF-54.2M CHF2023−23%2024: -50.9M CHF-50.9M CHF2024−6%2025: -70.4M CHF-70.4M CHF2025+38%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Contract revenue3.6M CHF27.3M CHF14.8M CHF
Total revenue3.6M CHF27.3M CHF14.8M CHF
Research & development expenses-56.4M CHF-62.6M CHF-54.6M CHF
General & administrative expenses-16.1M CHF-17.3M CHF-15.3M CHF
Other operating income/(expense), net94.0K CHF142.0K CHF1.5M CHF
Restructuring expenses, net-455.0K CHF
Total operating expenses-72.9M CHF-79.7M CHF-68.4M CHF
Operating loss-69.3M CHF-52.4M CHF-53.6M CHF
Financial income1.9M CHF3.2M CHF1.0M CHF
Financial expense-191.0K CHF-133.0K CHF-176.0K CHF
Exchange differences-2.8M CHF-1.6M CHF-1.5M CHF
Finance result, net-1.1M CHF1.5M CHF-599.0K CHF
Loss before tax-70.4M CHF-50.9M CHF-54.2M CHF
Income tax expense0 CHF-3.0K CHF-10.0K CHF
Loss for the period-70.4M CHF-50.9M CHF-54.2M CHF
Basic loss per share for the period attributable to equity holders-0.70 CHF-0.51 CHF-0.64 CHF
Diluted loss per share for the period attributable to equity holders-0.70 CHF-0.51 CHF-0.64 CHF

Compare AC Immune SA with another company

Corporate structure

AC Immune SA sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of AC Immune SA

  • AC Immune SA V8

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What AC Immune SA reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net2.0M CHF3 Dec 31, 20252.7M CHF3 Dec 31, 2024−25.0%
Operating-lease assets (leased space)4.5M CHF3 Dec 31, 20255.4M CHF3 Dec 31, 2024−16.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents26.8M CHF3 Dec 31, 202536.3M CHF3 Dec 31, 2024−26.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)50.4M CHF3 Dec 31, 202550.4M CHF3 Dec 31, 20240%

Leadership

Who has led AC Immune SA, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrea Pfeifer2026
  2. Martin Zuegel2026–now

Chief operating officer

  1. Piergiorgio Donati2026–now
Board members and other officers (6)

Timeline

  1. Jun 15, 2026New chief executive Martin Zuegel becomes CEO13
  2. Mar 18, 2026New chief executive Andrea Pfeifer becomes CEO12

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.20) a share, on Nov 4, 2025.20

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

143 filings to the SEC since October 2021: 5 annual reports, 18 insider forms, 10 large holders, 110 other. The latest 20:

  1. Oct 9, 20263 PRIMARY DOCUMENT EDGAR
  2. Oct 9, 20263/A EDGAR
  3. Oct 2, 20266-K EDGAR
  4. Sep 23, 20266-K EDGAR
  5. Sep 3, 20266-K EDGAR
  6. Aug 20, 20266-K EDGAR
  7. Aug 11, 20266-K EDGAR
  8. Aug 5, 20266-K EDGAR
  9. Jun 30, 20266-K EDGAR
  10. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  11. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  12. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  13. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  14. Jun 15, 20264 PRIMARY DOCUMENT EDGAR
  15. Jun 11, 20266-K EDGAR
  16. Jun 11, 20266-K EDGAR
  17. May 18, 20264 PRIMARY DOCUMENT EDGAR
  18. May 15, 2026144 EDGAR
  19. May 15, 20266-K EDGAR
  20. May 12, 20266-K EDGAR

The 143 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 1 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 15, 2026Pfeifer AndreaChief Executive OfficerSale10,000$2.79$27.9KForm 4
Apr 15, 2026Pfeifer AndreaChief Executive OfficerSale10,000$3.14$31.4KForm 4
Apr 15, 2026Pfeifer AndreaChief Executive OfficerBuy10,000$3.14$31.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How AC Immune SA is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAC Immune SA1
  • CIK0001651625
  • Filer statusAccelerated filer not an emerging growth company; not a shell company5
  • Incorporated inSwitzerland5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressEpfl Innovation Park, Building B, 1015 Lausanne, V8 000001
  • Phone41 21 345 91 211
  • Shares outstanding101,742,231 shares as of Dec 31, 20255
  • AuditorPricewaterhouseCoopers SA, Lausanne, Switzerland PCAOB ID 1358; it also attests to the company’s internal control over financial reporting5
  • On EDGAR sinceAug 28, 20151
  • Filings312 in all: 6-K (143), 144 (28), SC 13G/A (23), CORRESP (17), UPLOAD (16), 20-F (10), 3 (9), 424B5 (8)1
    All 28 form types

    SC 13G (8), 4 (7), F-1/A (7), EFFECT (6), DRS/A (5), F-3 (5), DRSLTR (3), S-8 (3), F-3/A (2), FWP (2), 20-F/A (1), 3/A (1), 4/A (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DRS (1), F-1 (1)

  • Latest filingsAnnual report (20-F) Mar 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Shares, nominal value CHF 0.02 per shareACIUThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 13, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceACIU quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25